Literature DB >> 6149683

Effect of ICI 118,587 on left ventricular function during graded treadmill exercise in conscious dogs.

A Ohyagi, S Sasayama, Y Nakamura, J D Lee, Y Kihara, C Kawai.   

Abstract

Effect of ICI 118,587 (corwin, ICI), a new cardioselective beta-partial agonist, on left ventricular (LV) function was studied and compared with that of isoproterenol and propranolol in 10 conscious normal dogs, instrumented with a micromanometer and pairs of ultrasonic crystals for analysis of LV wall motion. Heart rate, LV dP/dt and mean circumferential shortening velocity were measured at rest and during 3 levels of treadmill exercise (Ex). Before drug administration (control), the heart rate, dP/dt, percent shortening and mean circumferential shortening velocity were enhanced linearly along with the graded Ex. The Ex response curve shifted upward during isoproterenol infusion and downward after the administration of propranolol. With ICI, hemodynamic and contractile indexes were enhanced at rest as with isoproterenol, while these indexes were depressed during maximal Ex as after propranolol. The Ex response curve after ICI crossed the control response curve at a moderate level of Ex. Thus ICI exerts positive inotropic and chronotropic effects at rest when basal sympathetic tone is low, whereas it exerts negative inotropic and chronotropic properties at maximal Ex when sympathetic tone is high. The inherent dual action of this drug is expected to open a new field of treatment for ischemic heart disease with or without heart failure.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6149683     DOI: 10.1016/s0002-9149(84)80154-x

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  7 in total

Review 1.  Xamoterol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use.

Authors:  R Furlong; R N Brogden
Journal:  Drugs       Date:  1988-10       Impact factor: 9.546

2.  Modulation of the autonomic control of the failing heart.

Authors:  H M Snow
Journal:  Basic Res Cardiol       Date:  1989       Impact factor: 17.165

Review 3.  The pharmacology of xamoterol: a basis for modulation of the autonomic control of the heart.

Authors:  H M Snow
Journal:  Br J Clin Pharmacol       Date:  1989       Impact factor: 4.335

4.  Effects of xamoterol, a beta 1 adrenoceptor partial agonist, in patients with ischaemic dysfunction of the left ventricle.

Authors:  E Vigholt-Sørensen; O Faergeman; H M Snow
Journal:  Br Heart J       Date:  1989-11

5.  Relationship between positive inotropic responses and plasma concentrations of xamoterol in middle-aged and elderly patients.

Authors:  H F Marlow; F L Hine; H M Snow; H Pouleur; M F Rousseau
Journal:  Br J Clin Pharmacol       Date:  1990-05       Impact factor: 4.335

6.  Renal effects of xamoterol in patients with moderate heart failure.

Authors:  H E Bøtker; H K Jensen; L R Krusell; E V Sørensen
Journal:  Cardiovasc Drugs Ther       Date:  1993-02       Impact factor: 3.727

7.  Predominant beta-adrenoceptor blocking effect of xamoterol averaged over the day in patients with mild to moderate heart failure: insight into the mechanism of its long-term clinical efficacy.

Authors:  H Ozaki; H Sato; M Hori; T Matsuyama; K Imai; H Yokoyama; A Kitabatake; M Inoue; T Kamada
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.